Maximilian Aigner

Title: Maximilian Aigner: Innovator in Cancer Therapy

Introduction

Maximilian Aigner is a notable inventor based in Germering, Germany. He has made significant contributions to the field of cancer therapy through his innovative research and development. His work focuses on utilizing advanced techniques to improve treatment outcomes for patients with solid tumors.

Latest Patents

Aigner holds a patent for a groundbreaking invention titled "Multi-modal cancer therapy using viral hitch-hiking." This invention involves an antibody fusion protein that specifically recognizes the VA, HN, or F surface antigen of the Newcastle Disease Virus (NDV). It also targets surface molecules of tumor-unspecific T cells or dendritic cells, along with an immunocytokine. The patent encompasses polynucleotides encoding the antibody fusion protein and the tumor-unspecific key cells or dendritic cells bound by it. The method described in the patent aims to treat tumors in subjects by administering the antibody fusion protein, tumor-unspecific T cells, dendritic cells, or the polynucleotide.

Career Highlights

Maximilian Aigner is affiliated with the Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts, where he continues to advance his research in cancer therapies. His dedication to improving treatment methodologies has positioned him as a key figure in the field.

Collaborations

Aigner has collaborated with esteemed colleagues such as Volker Schirrmacher and Philippe Fournier. These partnerships have further enriched his research and contributed to the development of innovative cancer treatment strategies.

Conclusion

Maximilian Aigner's work in cancer therapy exemplifies the impact of innovative thinking in medical research. His patent on multi-modal cancer therapy represents a significant advancement in the fight against tumors. Through his career and collaborations, Aigner continues to pave the way for future breakthroughs in cancer treatment.